These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25022372)

  • 21. Risk factors for both recurrence and survival in patients with pathological stage I non-small-cell lung cancer.
    Kozu Y; Maniwa T; Takahashi S; Isaka M; Ohde Y; Nakajima T
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):e53-8. PubMed ID: 23557919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected.
    Takahashi Y; Horio H; Hato T; Harada M; Matsutani N; Kawamura M
    Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):14-20. PubMed ID: 25878187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
    Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
    Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage?
    Kawachi R; Nakazato Y; Takei H; Koshi-ishi Y; Goya T
    Interact Cardiovasc Thorac Surg; 2009 Aug; 9(2):199-202. PubMed ID: 19457896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status.
    Kato T; Ishikawa K; Aragaki M; Sato M; Okamoto K; Ishibashi T; Oba K; Kaji M
    J Surg Oncol; 2013 May; 107(6):619-24. PubMed ID: 23192365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis.
    Sawabata N; Maeda H; Yokota S; Takeda S; Koma M; Tokunaga T; Ito M
    Cancer; 2004 Aug; 101(4):803-9. PubMed ID: 15305413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
    Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
    Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum carcinoembryonic antigen level in pN1 non-small cell lung cancer patients.
    Tomita M; Matsuzaki Y; Shimizu T; Hara M; Ayabe T; Onitsuka T
    Anticancer Res; 2005; 25(5):3601-5. PubMed ID: 16101187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between serum carcinoembryonic antigen level and T status in non-small cell lung cancer.
    Tomita M; Matsuzaki Y; Shimizu T; Hara M; Ayabe T; Onitsuka T
    Anticancer Res; 2006; 26(5B):3845-8. PubMed ID: 17094411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor.
    Iwasaki A; Shirakusa T; Yoshinaga Y; Enatsu S; Yamamoto M
    Eur J Cardiothorac Surg; 2004 Sep; 26(3):488-93. PubMed ID: 15302040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
    Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
    J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
    Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
    Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.